Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

How to Treat MDS without Stem Cell Transplantation

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis Annalisa Ruggeri, Fernanda.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group.

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine Challenges—Thyroid Dysfunction,

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Sabina Kersting, Leo F. Verdonck

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete.

B Cells and Transplantation: An Educational Resource

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Statistical Considerations in Studies of Late Effects in HCT

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Treatment versus Transplant for Challenging Hematologic Disorders

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Presentation transcript:

High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant? Michael A. Pulsipher, Christina Peters, Ching-Hon Pui Biology of Blood and Marrow Transplantation Volume 17, Issue 1, Pages S137-S148 (January 2011) DOI: 10.1016/j.bbmt.2010.10.005 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Probability of EFS according to transplant indication and donor type. Biology of Blood and Marrow Transplantation 2011 17, S137-S148DOI: (10.1016/j.bbmt.2010.10.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Probability of survival according to transplant indication and donor type. Biology of Blood and Marrow Transplantation 2011 17, S137-S148DOI: (10.1016/j.bbmt.2010.10.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Consideration of the use of HSCT for newly defined high-risk patients. Biology of Blood and Marrow Transplantation 2011 17, S137-S148DOI: (10.1016/j.bbmt.2010.10.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions